Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific sur vival in resectable gastroesophageal junction and gastric adenocarcinoma

Annals of Surgery

Volumn 263, Issue 2, 2016, Pages 292-297

  Wang, Sam C ^a   Chou, Joanne F ^b   Strong, Vivian E ^b   Brennan, Murray F ^b   Capanu, Marinela ^b   Coit, Daniel G ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gastric cancer; Gastroesophageal junction cancer; Neutrophil to lymphocyte ratio; NLR

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CAUCASIAN; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HISTOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; PERINEURAL INVASION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; VERY ELDERLY; ADENOCARCINOMA; EVALUATION STUDY; FOLLOW UP; GASTRECTOMY; GASTROESOPHAGEAL JUNCTION; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MORTALITY; NEUTROPHIL; PREOPERATIVE PERIOD; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

BIOLOGICAL MARKER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84955571909     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001189     Document Type: Article

References (54)

1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
2. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29: 1715-1721.
3. Kitano S, Shiraishi N, Uyama I, et al. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg. 2007;245:68-72.
4. Ishigami S, Natsugoe S, Hokita S, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol. 2001;32:41-44.
5. Cardoso R, Coburn N, Seevaratnam R, et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer. 2012;15(suppl 1):S19-S26.
6. Hasegawa S, Yoshikawa T, Shirai J, et al. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multi-detector-row CT. Ann Surg Oncol. 2013;20:2016-2022.
7. Bentrem D, Gerdes H, Tang L, et al. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol. 2007;14:1853-1859.
8. Walker KG, Bell SW, Rickard MJFX, et al. Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg. 2004;240:255-259.
9. Murthy BL, Thomson CS, Dodwell D, et al. Postoperative wound compli-cations and systemic recurrence in breast cancer. Br J Cancer. 2007;97:1211-1217.
10. Lagarde SM, de Boer JD, Kate ten FJW, et al. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg. 2008;247:71-76.
11. Tokunaga M, Tanizawa Y, Bando E, et al. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2012;20:1575-1583.
12. Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery. Ann Surg. 2012;256:235-244.
13. Liu L, Wang Z, Jiang S, et al. Perioperative Allogeneic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e64261.
14. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327-348.
15. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5-14.
16. Dionigi R, Dominioni L, Benevento A, et al. Effects of surgical trauma of laparoscopic vs. open cholecystectomy. Hepatogastroenterology. 1994;41: 471-476.
17. O'Mahony JB, Palder SB, Wood JJ, et al. Depression of cellular immunity after multiple trauma in the absence of sepsis. J Trauma. 1984;24:869-875.
18. Malietzis G, Giacometti M, Askari A, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014;260:287-292.
19. Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416-421.
20. Perez DR, Baser RE, Cavnar MJ, et al. Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor. Ann Surg Oncol. 2013;20: 593-599.
21. Mano Y, Shirabe K, Yamashita Y-I, et al. Preoperative neutrophil-to-lympho-cyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma. Ann Surg. 2013;258:301-305.
22. Pinato DJ, Shiner RJ, Seckl MJ, et al. Prognostic performance of inflam-mation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer. 2014;110:1930-1935.
23. Williams KA, Labidi-Galy SI, Terry KL, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014;132:542-550.
24. Kelkitli E, Atay H, Çilingir F, et al. Predicting survival for multiple myeloma patients using baseline neutrophil(lymphocyte ratio. Ann Hematol. 2013;93: 841-846.
25. de Martino M, Pantuck AJ, Hofbauer S, et al. Prognostic impact of preop-erative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013;190:1999-2004.
26. Aizawa M, Gotohda N, Takahashi S, et al. Predictive value of baseline neutrophil(lymphocyte ratio for T4 disease in wall-penetrating gastric cancer. World J Surg. 2011;35:2717-2722.
27. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol. 2011;104:504-510.
28. Ubukata H, Motohashi G, Tabuchi T, et al. Evaluations of interferon-((inter-leukin-4 ratio and neutrophil(lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol. 2010;102:742-747.
29. Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21:3647-3650.
30. Conover WJ. Practical Nonparametric Statistics. 2nd ed. New York, NY: Wiley & Sons; 1980.
31. Mendenhall W, Wackerly D, Scheaffer LR. Mathematical Statistics With Applications. 4th ed. Boston, MA: P.W.S-Kent; 1989.
32. Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007;73:215-220.
33. Shimada H, Takiguchi N, Kainuma O, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer. 2010;13:170-176.
34. Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-321.
35. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268-273.
36. Sakuramoto S, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2008;357:1810-1820.
37. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25:2107-2116.
38. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12:6-22.
39. Karanicolas PJ, Elkin EB, Jacks LM, et al. Staging laparoscopy in the management of gastric cancer: a population-based analysis. J Am Coll Surg. 2011;213:644e1-651e1.
40. Aurello P, Tierno SM, Berardi G, et al. Value of preoperative inflammation-based prognostic scores in predicting overall survival and disease-free survival in patients with gastric cancer. Ann Surg Oncol. 2014;21:1998-2004.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
42. Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesopha-geal junction are correlated with early cancer recurrence. Ann Surg. 2009;250:798-807.
43. McArdle CS, McMillan DC, Hole DJ. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg. 2005;92:1150-1154.
44. Hyung WJ, Noh SH, Shin DW, et al. Adverse effects of perioperative trans-fusion on patients with stage III and IV gastric cancer. Ann Surg Oncol. 2002;9:5-12.
45. Weitz J, D'Angelica M, Gönen M, et al. Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. J Clin Oncol. 2003;21:4597-4603.
46. Bald T, Quast T, Landsberg J, et al. Ultraviolet-radiation-induced inflam-mation promotes angiotropism and metastasis in melanoma. Nature. 2014;507:109-113.
47. Spicer JD, McDonald B, Cools-Lartigue JJ, et al. Neutrophils promote liver metastasis via mac-1-mediated interactions with circulating tumor cells. Cancer Res. 2012;72:3919-3927.
48. Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123:3446-3458.
49. Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32:22-28.
50. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383-5391.
51. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213.
52. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666.
53. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30:2678-2683.
54. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.